Headlands Technologies LLC Sells 24,024 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

Headlands Technologies LLC reduced its stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 48.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 25,672 shares of the biotechnology company’s stock after selling 24,024 shares during the quarter. Headlands Technologies LLC’s holdings in Heron Therapeutics were worth $39,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Argent Advisors Inc. purchased a new stake in shares of Heron Therapeutics in the fourth quarter valued at about $31,000. Y Intercept Hong Kong Ltd purchased a new stake in Heron Therapeutics in the 3rd quarter valued at about $39,000. Cutter & CO Brokerage Inc. lifted its position in shares of Heron Therapeutics by 69.6% during the 4th quarter. Cutter & CO Brokerage Inc. now owns 33,135 shares of the biotechnology company’s stock worth $51,000 after buying an additional 13,600 shares in the last quarter. Arkadios Wealth Advisors purchased a new position in shares of Heron Therapeutics in the 4th quarter worth approximately $76,000. Finally, Intech Investment Management LLC grew its holdings in shares of Heron Therapeutics by 61.8% in the fourth quarter. Intech Investment Management LLC now owns 58,242 shares of the biotechnology company’s stock valued at $89,000 after acquiring an additional 22,254 shares in the last quarter. 80.01% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. StockNews.com cut Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 8th. Needham & Company LLC reissued a “buy” rating and issued a $4.00 price target on shares of Heron Therapeutics in a report on Friday, February 28th.

Heron Therapeutics Trading Down 9.7 %

Shares of NASDAQ HRTX opened at $1.77 on Wednesday. The firm has a market cap of $269.62 million, a price-to-earnings ratio of -9.83 and a beta of 1.39. The stock has a fifty day simple moving average of $2.05 and a two-hundred day simple moving average of $1.79. Heron Therapeutics, Inc. has a 1-year low of $1.04 and a 1-year high of $3.93.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.05. The firm had revenue of $40.78 million during the quarter, compared to the consensus estimate of $37.37 million. Analysts forecast that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.